ABOS
Acumen Pharmaceuticals Inc.
$1.36
+$0.05(+3.82%)
41
Overall
--
Value
41
Tech
--
Quality
Market Cap
$88.44M
Volume
93.86K
52W Range
$0.86 - $3.36
Target Price
$7.80
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $66.0K | $43.0K | $5.0K | -- | ||
| Total Revenue | $66.0K | $43.0K | $5.0K | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $66.0K | $43.0K | $5.0K | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $19.6M | $45.2M | $61.1M | $114.0M | ||
| Research & Development | $12.3M | $32.4M | $42.3M | $93.8M | ||
| Research Expense | $12.3M | $32.4M | $42.3M | $93.8M | ||
| Selling, General & Administrative | $7.3M | $12.9M | $18.8M | $20.2M | ||
| General & Administrative Expenses | $7.3M | $12.9M | $18.8M | $20.2M | ||
| Salaries & Wages | -- | -- | $6.1M | $9.6M | ||
| Other Operating Expenses | -- | $154.0K | $160.0K | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-19.6M | $-45.2M | $-61.1M | $-114.0M | ||
| EBITDA | $-100.4M | $-42.7M | $-52.2M | $-102.2M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | -- | -- | $581.0K | -- | ||
| Interest Income Operating | -- | $2.4M | $10.8M | -- | ||
| Intinc | $84.0K | $2.4M | $10.8M | $14.3M | ||
| Net Non-Operating Interest Income/Expense | $84.0K | $-2.4M | $10.8M | $14.3M | ||
| Gain on Sale of Securities | -- | -- | $-1.4M | $1.6M | ||
| Other Income/Expense | $81.1M | $-11.0K | $1.4M | $-1.4M | ||
| Other Special Charges | $-81.1M | $-11.0K | $-83.0K | $-151.0K | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-100.6M | $-42.9M | $-52.4M | $-102.3M | ||
| Pre-Tax Income | $-100.6M | $-42.9M | $-51.8M | $-98.3M | ||
| NET INCOME | ||||||
| Net Income | $-100.6M | $-42.9M | $-52.4M | $-102.3M | ||
| Net Income (Continuing Operations) | $-100.6M | $-42.9M | $-52.4M | $-102.3M | ||
| Net Income (Discontinued Operations) | $-100.6M | $-42.9M | $-52.4M | $-102.3M | ||
| Net Income (Common Stockholders) | $-100.6M | $-42.9M | $-52.4M | $-102.3M | ||
| Normalized Income | $-79.5M | -- | -- | $-97.3M | ||
| TOTALS | ||||||
| Total Expenses | $19.6M | $45.2M | $61.1M | $114.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $20.1M | $40.6M | $48.6M | $60.0M | ||
| Average Shares Outstanding (Diluted) | $20.1M | $40.6M | $48.6M | $60.0M | ||
| Shares Outstanding | $40.5M | $41.0M | $60.1M | $60.6M | ||
| Basic EPS | $-5.02 | $-1.06 | $-1.08 | $-1.71 | ||
| Basic EPS (Continuing Operations) | $-5.02 | $-1.06 | $-1.08 | $-1.71 | ||
| Diluted EPS | $-5.02 | $-1.06 | $-1.08 | $-1.71 | ||
| Diluted EPS (Continuing Operations) | -- | $-1.06 | $-1.08 | $-1.71 | ||
| OTHER METRICS | ||||||
| Other Gand A | $7.3M | $12.9M | $18.8M | $20.2M | ||
| Rent And Landing Fees | $147.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABOS | $1.36 | +3.8% | 93.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Acumen Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW